Asensioexposes!com offers accurate facts that disproves past criticism of the Manuel Asensio Reports. - Manuel Asensio Report: Apr. 29, 1998 BioTime possesses no valuable product or technology.

“[Asensio] has gained prominence for his public war of words with Diana Corp.-- a war that he has clearly won, with Diana's shares plummeting 97% over the 12 months.”

Gary Weiss. BusinessWeek

Other resources of interest

A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio

Click here

Manuel Asensio Report: Apr. 29, 1998 BioTime possesses no valuable product or technology.

Manuel Asensio and Asensio report that BioTime, Inc.’s (OTC Symbol: BTIM) (Price: $11.125) management claims that Hextend, its principal product candidate, has annual sales potential of $750 million. Manuel Asensio and Asensio believe that this is untrue. In fact, there is no factual or reasonable basis for this claim. BioTime’s management has also claimed that Hextend is a synthetic substitute for certain human blood products. According to Manuel Asensio and Asensio, this claim is also completely false. Hextend is a simple, commodity-based plasma volume expander. Hextend performs none of the blood’s essential life-supporting functions. Hextend offers no advantage over its competitors. If approved it will have to compete on price in an already declining $30 million market.
BioTime possesses no asset or future potential that can remotely support its current stock price. Manuel Asensio and Asensio believe that BioTime’s false product and sales potential claims were purposely disseminated by management to defraud investors. Even based on BioTime’s own unrealistic FDA-approval schedule and price assumption, Manuel Asensio and Asensio believe the shares are worth much less than $2.

[ Back ]